← Home
Amgen
-8.01%
Healthcare & biotech / Biotechnology and Pharmaceuticals
Press Releases
| Date | Press release |
|---|---|
| 2025-04-28 16:01:00 | Amgen Announces Webcast Of 2025 First Quarter Financial Results Thousand oaks, calif. , april 28, 2025 /prnewswire/ -- amgen (nasdaq:amgn) today announced that it will report its first quarter 2025 financial results on thursday, may 1, 2025, after the close of the u.s. financial markets. |
| 2025-04-25 12:47:00 | Amgen Announces $900 Million Manufacturing Expansion, Creation Of 350 New Jobs In Ohio Total investment in the state to exceed $1.4 billion, 750 u.s. jobs thousand oaks, calif. , april 25, 2025 /prnewswire/ -- amgen (nasdaq: amgn) today announced a $900 million expansion of its ohio manufacturing facility, bringing the total number of jobs created to 750 and the total investment in central ohio to over $1.4 billion. |
| 2025-04-11 09:00:00 | Imdelltra® Demonstrated Superior Overall Survival In Small Cell Lung Cancer First global phase 3 trial showing substantial survival advantage over chemotherapy, for patients with progression on or after platinum-based chemotherapy thousand oaks, calif. , april 11, 2025 /prnewswire/ -- amgen (nasdaq:amgn) today announced that the global phase 3 dellphi-304 clinical trial evaluating imdelltra® (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (sclc) who progressed on or after a single line of platinum-based chemotherapy met its primary endpoint at a planned interim analysis. |
| 2025-04-03 15:35:00 | Uplizna® (inebilizumab-cdon) Is Now The First And Only Fda-approved Treatment For Igg4-related Disease Breakthrough cd19+ b-cell targeted therapy delivered an 87% reduction in the risk of flares versus placebo uplizna shown to deliver corticosteroid-free, flare-free, complete remission for patients in the mitigate trial advances amgen’s leadership in cd19 directed, b-cell depletion therapies for serious autoimmune diseases including nmosd, igg4-rd and gmg thousand oaks, calif. , april 3, 2025 /prnewswire/ -- amgen (nasdaq:amgn) announced today that the u.s. food and drug administration (fda) has approved uplizna as the first and only treatment for adults living with immunoglobulin g4-related disease (igg4-rd). |
| 2025-03-13 09:00:00 | Uplizna® (inebilizumab-cdon) Significantly Improves Generalized Myasthenia Gravis Symptoms In Acetylcholine Receptor Autoantibody-positive Patients Over 52 Weeks Patients reported improvement in ability to conduct daily activities with twice-yearly dosing * late-breaking data to be presented at aan 2025 thousand oaks, calif. , march 13, 2025 /prnewswire/ -- amgen (nasdaq:amgn) today announced new data from the phase 3, registrational mint trial evaluating the efficacy and safety of uplizna® (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gmg). |
© 2024 - 2025 InsightfulValue.com. All rights reserved.
Legal